GenSight Biologics S.A.’s GS010/LUMEVOQ rollout in France and Israel has done more than expand access—it may be redefining how gene therapies are delivered in ophthalmology. As the company prepares for bilateral administration under early access programs for Leber Hereditary Optic Neuropathy (LHON), it is stepping into a growing shift across the field: a move away from conservative, single-eye dosing protocols and toward bilateral treatment as both a clinical necessity and regulatory evolution. The implications are wide-ranging—from trial design and safety concerns to manufacturing, payer economics, and patient expectations in symmetric degenerative eye diseases.
Why retinal gene therapies began with single-eye dosing—and why that model is changing
Historically, gene therapies for inherited retinal diseases have defaulted to unilateral injection, even when both eyes are affected. This cautious approach emerged from early adeno-associated virus (AAV) vector development, where systemic immune responses, intraocular inflammation, and uncertainty about dose tolerability made bilateral administration risky. Regulators and trial designers erred on the side of safety—especially in irreversible settings like subretinal injections—where inflammation or off-target effects could lead to permanent vision loss.
However, as more clinical data has emerged, these safety fears are giving way to a new operational reality. Many inherited retinal disorders, including LHON, choroideremia, and X-linked retinoschisis, exhibit symmetric and simultaneous or near-simultaneous degeneration in both eyes. Waiting to treat the second eye risks preventable vision loss. The need to protect residual function in both eyes—while the patient is still eligible—has catalyzed a more proactive stance on bilateral delivery.
How GenSight’s bilateral approach reflects disease biology and regulatory adaptation
GenSight Biologics has been among the first companies to publicly shift toward bilateral delivery in its early access strategy. GS010/LUMEVOQ (lenadogene nolparvovec), delivered via intravitreal injection, is designed to restore mitochondrial function in retinal ganglion cells damaged by ND4 mutations in LHON. The disease typically affects both eyes in rapid succession—often within weeks or months—making unilateral therapy clinically insufficient in real-world settings.
Data from GenSight’s earlier trials hinted at a contralateral effect, where visual improvement occurred in both the injected and non-injected eye. This phenomenon was initially viewed as a strength, but it also obscured the true value of bilateral treatment. The company’s latest programs now explicitly pursue bilateral dosing, enabling more robust data collection on functional improvements, dosing symmetry, and real-world tolerability.
From a regulatory standpoint, this evolution is notable. France’s named patient authorization and Israel’s early access clearance both allowed bilateral use, reflecting increased comfort among regulators with the safety profile of intravitreal AAV delivery and the clinical logic of simultaneous intervention. These precedents may influence regulatory positions elsewhere, especially as pivotal trials like RECOVER incorporate bilateral protocols from the outset.
Voretigene neparvovec and the precedent it set—with limits
The approval of Voretigene neparvovec-rzyl (Luxturna), developed by Spark Therapeutics and now marketed by Roche, was a watershed moment for retinal gene therapy. Approved in both the United States and European Union for biallelic RPE65 mutation-associated retinal dystrophy, Luxturna is administered subretinally, one eye at a time. The label recommends separate surgeries spaced by at least six days, primarily due to concerns over immune response, surgical complexity, and individual eye recovery.
While Luxturna’s dual-eye approval was a major milestone, the required spacing and surgical burden reflect the limits of first-generation delivery. Clinicians welcomed the option to treat both eyes but remained constrained by procedural logistics and conservative risk assessments. In practice, many patients were delayed in receiving second-eye treatment—an outcome that can significantly reduce functional gains in rapidly progressing diseases.
The GenSight model, by contrast, bypasses the need for surgery by using intravitreal injection, which may allow for simultaneous or closely staged administration without invasive procedures. This difference in delivery route is not just technical—it enables a reevaluation of safety thresholds, patient throughput, and long-term visual rehabilitation strategy.
AGTC’s dosing strategy shows increasing openness to bilateral protocols
Applied Genetic Technologies Corporation (AGTC), now part of Syncona Ltd’s portfolio, has taken a similarly cautious-yet-adaptive approach. In its programs for X-linked retinoschisis and achromatopsia, AGTC initially pursued staggered bilateral administration, using contralateral eye treatment as a functional and safety control. However, data from later-stage trials and open-label extensions increasingly support the feasibility of bilateral treatment—especially when the non-injected eye continues to decline.
The use of subretinal injection has historically reinforced single-eye dosing in AGTC trials. But as procedural experience has improved and patients push for more holistic visual restoration, the company has begun discussing simultaneous or closely staged bilateral treatment under newer protocols. These trends suggest that even conservative developers are reconsidering long-held assumptions.
What ophthalmologists are saying about symmetry, timing, and patient impact
Clinicians managing inherited retinal disorders have long noted that many of these diseases progress in a functionally symmetric manner. For conditions like LHON and retinitis pigmentosa, vision in both eyes typically declines within months, often to a similar severity. Treating one eye and monitoring the other may meet trial endpoints but does not reflect clinical best practice when patients risk complete blindness within short windows.
Leading ophthalmologists now argue that delaying second-eye intervention is increasingly difficult to justify, especially when delivery routes and immunogenicity profiles suggest a manageable risk. For intravitreal AAV delivery, systemic exposure is minimal, and bilateral injection may not meaningfully increase immunogenicity relative to unilateral administration. This is particularly true when both injections are administered during the same session or within a short interval.
From a patient perspective, the difference between treating one eye and both can be life-altering. Even modest functional gains in both eyes can improve navigational vision, reading, depth perception, and overall quality of life. Advocacy groups and clinicians alike are beginning to call for bilateral options as part of the standard of care—not a post-hoc enhancement after regulatory approval.
Broader relevance: other gene therapy fields are also embracing multi-site delivery
While this trend is most pronounced in ophthalmology, similar conversations are unfolding in neurological gene therapy. In conditions like spinal muscular atrophy or Friedreich’s ataxia, some gene therapy developers are exploring multi-site or bilateral intrathecal delivery to ensure adequate central nervous system coverage. The underlying logic mirrors the retinal context: when disease affects symmetric structures or distributed networks, targeted single-site administration may underperform.
The shift toward bilateral or multi-site administration also raises new manufacturing and economic questions. Companies must produce more vector product per patient, scale dosing regimens, and engage with payers around the cost-benefit logic of dual administration. In gene therapy’s pricing environment, bilateral dosing cannot simply double the price—it must deliver proportional clinical and economic value.
What developers, regulators, and payers will be watching next
As GenSight Biologics prepares for broader rollout of GS010/LUMEVOQ, the bilateral approach is likely to influence not only regulators but also competitors and payers. If real-world data from France and Israel supports the safety and efficacy of bilateral administration, this may set a new baseline for patient expectations in future approvals. Trials like RECOVER may formally embed bilateral dosing, using early access data as a regulatory bridge and patient access enabler.
Meanwhile, competitors still relying on single-eye designs may face pressure to update protocols or risk clinical irrelevance. For regulators, the question is how to balance safety concerns with real-world urgency in diseases that do not wait. For payers, the economics of gene therapy must evolve to support treatment regimens that reflect true clinical need—without defaulting to arbitrary per-eye pricing.
The broader field of ophthalmic gene therapy stands at a crossroads. Bilateral delivery is no longer a fringe consideration. It is becoming an expected design element for future trials and an operational necessity for meaningful patient benefit.
Is bilateral delivery becoming the new standard in retinal gene therapy? added by Venkatesh B on
View all posts by Venkatesh B →